, Tracking Stock Market Picks
Enter Symbol:
Biogen Idec Inc (BIIB) [hlAlert]

up 208.12 %

Biogen Idec Inc (BIIB) rated Buy with price target $460 by Deutsche Bank

Posted on: Friday,  Jan 30, 2015  1:25 PM ET by Deutsche Bank

Deutsche Bank rated Buy Biogen Idec Inc (NASDAQ: BIIB) on 01/30/2015. Previously Deutsche Bank rated Buy Biogen Idec Inc (NASDAQ: BIIB) on
06/21/2011., when the stock price was $98.82. Since then, Biogen Idec Inc has gained 208.13% as of 01/07/2016's recent price of $304.49.
If you would have followed the previous Deutsche Bank's recommendation on BIIB, you would have gained 208.12% of your investment in 1661 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Deutsche Bank is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank. This division is one of the largest global asset managers.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/30/2015 1:25 PM Buy
390.21 460.00
as of 8/27/2015
1 Week down  -1.45 %
1 Month down  -26.85 %
3 Months down  -22.78 %
1 YTD up  8.91 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/28/2014 1:25 PM Buy
304.48 415.00
4/23/2013 1:25 PM Buy
214.69 240.00
6/21/2011 1:25 PM Buy
98.82 129.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy